Upperton Pharma Solutions
Ian Lafferty is a seasoned professional in the pharmaceutical industry with extensive experience in formulation development and CDMO services. Currently serving as Chief Technical Officer and Technical Consultant at Upperton Pharma Solutions since 2019, Ian also owns and directs LAceutics, focusing on formulation design, CMC strategy, and operational development. Previous roles include Director of Pharmaceutical Development Services at Juniper Pharma Services and Site Director at Aesica Formulation Development. Ian has a strong background in manufacturing management, having held the position of Manufacturing Director at Nova Laboratories, and has worked as a Formulation Scientist at both Danbiosyst - West Pharmaceutical Services and Fisons. Ian holds a PhD in Pharmaceutics from De Montfort University, further enhancing expertise in the field.
Upperton Pharma Solutions
Upperton Pharma Solutions is a specialist CDMO (contract development and manufacturing organisation) providing formulation and dosage form development services to the biotechnology and pharmaceutical industries. We offer our clients a complete development service, from early feasibility studies to process optimisation, scale up and clinical trial (GMP / IMP) manufacturing. We are able to enhance the performance and delivery of our client’s products by utilising an extensive range of formulation technologies. In particular we have world leading expertise and know-how in pharmaceutical spray dryings, probably the most versatile and fastest growing technology in the industry. We have experience of working with a range of dosage forms and the expertise to develop the most challenging of molecules. Our formulation work is supported by a comprehensive range of analytical services for product testing and ICH stability studies. Upperton has an extensive, multinational client-base, ranging from virtual and small start-ups to global pharma companies. We pride ourselves on our client-focused, flexible approach and scientific excellence.